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Background.Standard-criteria donation after circulatory death (DCD) kidney transplants (KTx) have higher primary nonfunction,
delayed graft function (DGF), and rejection rates than age-matched donation after brain death (DBD) but similar graft survival. Data
on expanded-criteria DCD are conflicting and many centers remain concerned regarding their use. Methods. In this single-
center observational study with 5-year follow-up, we analyzed data from 112 primary DCD Maastricht category-III single KTx re-
ceiving similar organ preservation and maintenance immunosuppression. Patients were sorted as young DCD (donor <60 years,
72 recipients) or old DCD (donor ≥60 years, 40 recipients). Old DCD outcomes were compared with young DCD and to a DBD
control group (old DBD, donor ≥60 years, 40 recipients). Results. After 5 years, old DCD showed lower patient survival
(66% vs 85%; P = 0.014), death-censored graft survival (63% vs 83%; P = 0.001), and Modification of Diet in Renal Disease es-
timated glomerular filtration rate (34, 27.0-42.0 mL/min per 1.73 m2 vs 45.0, 33.0-58.0 mL/min per 1.73 m2; P = 0.021) than
young DCDwith higher DGF (70% vs 47.2%; P = 0.029) and graft thrombosis (12.5% vs 1.4%; P = 0.021). Comparison between
old DCD and old DBD showed similar 5-year patient survival (66% vs 67%; P = 0.394) and death-censored graft survival (63% vs
69%; P = 0.518) but higher DGF (70% vs 37.5%; P = 0.007) and lower estimated glomerular filtration rate (34, 27.0-42.0 mL/min
per 1.73m2 vs 41, 40.0-42.0mL/min per 1.73m2; P = 0.029). Multivariate Cox regression analysis showed that donor 60 years or
older (hazard ratio, 3.135; 95% confidence interval, 1.716-5.729; P < 0.001) and induction with anti–IL2-receptor-α monoclonal
antibody (hazard ratio, 0.503; 95% confidence interval, 0.269-0.940, P = 0.031 in favor of induction with rabbit antithymocyte
globulin) are independent predictors of transplant loss.Conclusions.Overall, single KTx from DCD Maastricht category-III do-
nors 60 years or older have inferior outcomes than KTx from donors younger than 60 years. Comparison with age-matched DBD
showed similar patient and graft survivals. However, the discrepancy in graft function between DCD and DBD deserves further
investigation.
(Transplantation Direct 2018;4: e396; doi: 10.1097/TXD.0000000000000835. Published online 21 September, 2018.)K idney transplantation (KTx) is the best therapy forend-stage renal disease.1 Advances in perioperative
care and immunosuppression have significantly reducedReceived 13 July 2018.
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2 Transplantation DIRECT ■ 2018 www.transplantationdirect.comthe waiting list. Progressively, we have moved from the
boundaries of donation after brain death (DBD) toward the
challenge of donation after circulatory death (DCD).3
Even though DCD kidneys have higher rates of primary
nonfunction (PNF),4 delayed graft function (DGF),3,5 and rejec-
tion3,5 than DBD, several studies have shown that standard-
criteria (SC) DCD can offer excellent results.6,7 Nevertheless,
because inferior outcomes have been reported for expanded-
criteria (EC)DCD,many centers remain concerned regarding
their use.4,8-12
Current definition of EC-DCD comes from the experience
gained with DBD but it does not consider the intrinsic differ-
ences existing between these donor categories. Available data
are difficult to interpret because they are often biased by lack
of discrimination betweenMaastricht categories, inclusion of
organs preserved on static cold storage (SCS) and hypother-
mic machine perfusion (HMP), arbitrary single or dual KTx,
nonhomogeneous selection of the recipients (ie, different im-
munological risk and immunosuppression), and use of ex-
ternal databases. Benefit of preimplantation biopsy is also
debated.11-13
The aim of this studywas to assess the outcomes of primary
single KTx from Maastricht category-III DCD donors aged
60 years or older in the context of an old for-old allocation
policy and to analyze risk factors for transplant failure.MATERIALS AND METHODS
Study Design
In this single-center prospective observational study with
5-year follow-up, we enrolled patients who underwent
Maastricht category-III DCDKTx at the Royal LondonHos-
pital (London, UK) between January 2007 and February
2013. Inclusion criteria were: recipient age≥ 18 years, single
KTx, and cyclosporine-mycophenolate-steroid immunosup-
pression. Exclusion criteria were: previous KTx, donor youn-
ger than 18 years, organ preservation other than SCS, and
induction other than rabbit antithymocyte globulin (rATG)
or anti–IL2-receptor-α monoclonal antibody (IL2Mab). Pa-
tients were assessed for eligibility immediately before trans-
plant. According to the donor, they were allocated to 2 groups:
young DCD (donor <60 years) or old DCD (donor≥60 years).
Donor characteristics, recipient characteristics, and trans-
plant outcomeswere prospectively recorded on a central data-
base by dedicated staff and were reviewed by the authors
at 1, 3, and 5 years. The follow-up was interrupted in
December 2017 or in case of death. The studywas conducted
according to the WMA Declaration of Helsinki.
Primary Endpoints
The primary endpoint was overall graft survival (GS) of
KTx from DCD donors 60 years or older.
Secondary Endpoints
Secondary endpoints were: patient survival (PS), death-
censoredGS, 1-year estimated glomerular filtration rate (eGFR)
less than 30 mL/min per 1.73 m2, PNF, DGF, biopsy-proven
rejection (BPR), graft function, surgical complications, poly-
omavirus-associated nephropathy (PVAN), new-onset dia-
betes after transplantation (NODAT), and posttransplant
lymphoproliferative disorder (PTLD). Postimplantation bi-
opsies (PIB) were reviewed to assess microthrombosis, acutetubular necrosis (ATN), glomerular obsolescence (GO), and
their relationship with transplant outcomes.
Risk factors for overall graft failure, death-censored graft
failure, 1-year eGFR less than 30mL/min per 1.73 m2, death,
and DGF were evaluated. The following variables were con-
sidered: recipient age, donor age, donor sex, HLAmismatch,
cold ischemia time (CIT), induction treatment, and GO.
As a complementary analysis, old DCD were compared to
a group of primary single KTx fromDBD donors 60 years or
older (old DBD) performed during the same period.
Transplant loss was defined as death with function or need
for permanent renal replacement therapy. PNFwas defined as
graft function unable to prevent continuative dialysis when
other causes of transplant failure were excluded. Delayed
graft function was defined as the need for dialysis during the
first postoperative week. Diagnosis of rejection was based
on serum creatinine of 30% or higher from baseline and con-
firmed by histology. Steroid-resistant rejectionwas defined as
a failure of serum creatinine to decreasewithin 3 days after the
third pulse. Biopsies were scored according to Banff 2007
classification.14 Graft functionwasmeasured byModification
of Diet in Renal Disease eGFR.15 Polyomavirus-associated
nephropathy was suspected in case of worsening graft func-
tionwith polyomavirus plasma quantitative polymerase chain
reaction of 1000 copies/mL or greater and confirmed by im-
munohistochemistry. New-onset diabetes after transplanta-
tion was diagnosed according to the criteria of the World
Health Organization.16 Postimplantation biopsies were per-
formed immediately after reperfusion using a 16-gauge needle.
Two renal pathologists evaluated: number of glomeruli, per-
centage of obsolete glomeruli, microthrombosis, and ATN.
Only specimens with 5 glomeruli or greater were consid-
ered.17Histologywas deemed positive for ATN if acute tubu-
lar injury was mentioned in the report (without regard to
severity).18 Glomerular obsolescence was defined as the pres-
ence of 10% or greater of obsolete glomeruli.
Immunosuppression
As induction, patients received intravenous rATG
(Thymoglobulin; Genzyme, Cambridge, MA) 4 mg/kg total
dose from days 0 to 3 and intravenous methylprednisolone
500mg on day 0 and 250mg on days 1 and 2. Recipients with
a history of malignancy or hematologic disorder received in-
travenous basiliximab (Simulect; Novartis, Basel, CH) 20mg
on days 0 and 4 or daclizumab (Zenapax; Roche, Basel, CH)
1mg/kg on days 0, 14, 28, 42, and 56. As maintenance, pa-
tients received oral cyclosporine (Neoral; Novartis) 10mg/kg
per day and mycophenolate mofetil (Myfenax; Teva, Petach
Tikva, IL) 2000mg/d from day 0. Cyclosporine was adjusted
to achieve a trough level of 200 ng/mL during the first month
and150 to 100 ng/mL thereafter. Fromday 3, patients received
oral prednisone 20 mg/d, tapered to 5 mg/d by month 1.
Concomitant Medications
Patients received pneumocystis prophylaxis with oral tri-
methoprim/sulfamethoxazole 80/400 mg/d 3 times per week
for 3 months. Recipients at increased risk of Cytomegalovi-
rus disease (donor positive/recipient negative immunization
and/or rATG administration) received oral valganciclovir
(dose titrated according to eGFR) for 3 months. As deep vein
thrombosis (DVT) prophylaxis, we administered subcutane-
ous tinzaparin 175 anti-Xa IU/kg per day. Thrombophilic
© 2018 Wolters Kluwer Favi et al 3patients received perioperative intravenous unfractionated hep-
arin (target activated partial thromboplastin time ratio 2.0-2.5).
Statistical Analysis
Categorical and numerical outcomes were described using
proportions ormedians (1st-3rd interquartile) andwere com-
pared using Fisher exact, χ2, or Mann-WhitneyU test as ap-
propriate. Patient survival, overall GS, and death-censored
GS were analyzed with the Kaplan-Meier method. Survival
curves were compared with log-rank.We assessed the predic-
tive ability of a pool of preoperative variables for the risk of
graft loss (overall and death-censored), 1-year eGFR less than
30 mL/min per 1.73 m2, death, and DGF in DCD KTx. We
used Cox proportional hazards model for time-dependent
events. All the covariates having a P value less than 0.2 were
introduced in multivariable models. We chose a backward
conditional method to select significant independent covari-
ates. Hazard ratios (HR), odds ratios (OR), and 95% confi-
dence intervals (CI) were reported for significant variables.
We ran logistic regressions for dichotomous variables. We re-
ported the crudeOR, 95%CI, and P value for each predictor
in the univariate analysis whereas we entered only statisti-
cally significant variables at univariate analysis into multiple
logistic regression analyses to predict the final independent
factors.We chose a backward conditionalmethod to select sig-
nificant independent covariates. Likewise, the adjusted OR,
95% CI, and P value were reported for each predictor. We
assessed the model fit by chi-square, degrees of freedom, and
P value; we included pseudo-R2 value to provide information
about the percentage of variance explained by the model.
Significance was defined as P value less than 0.05. We per-
formed analyses with SPSS 23.0 (IBMCorp., Armonk, USA).
RESULTS
Patient Demographics and Characteristics
From January 2007 to February 2013, we performed 635
deceased donor KTx: 264 DBD and 134 category-III DCD.
According to our inclusion/exclusion criteria, 112 DCDwere
enrolled into the study (Figure 1). Reasons for exclusionwere:
retransplant (n = 9), tacrolimus-based immunosuppressionFIGURE 1. Flow diagram of the study.(n = 9), HMP (n = 2), and donor age < 18 years (n = 2).
Seventy-two recipients were allocated to young DCD, where-
as 40 recipients were allocated to old DCD. No patients were
excluded from the analysis. Main characteristics are detailed
in Table 1.
Primary Outcome
One- and 5-year overall GS for old DCD and young DCD
were 59% versus 84% and 39% versus 75%, respectively
(log-rank P = 0.001). Overall GS distribution for the 2 arms
was significantly different with log-rank P less than 0.001
(Figure 2). Reasons for graft loss were death (n = 6), PNF
(n = 4), antibody-mediated rejection (n = 2), PVAN (n = 2),
graft thrombosis (n = 1), recurrent renal disease (n = 2), and
interstitial fibrosis (IF)/tubular atrophy (TA) (n = 1) in young
DCD; death (n = 11), graft thrombosis (n = 5), PNF (n = 2),
IF/TA (n = 2), PVAN (n = 1), and pyelonephritis (n = 2) in
oldDCD.Univariate Cox regression analyses showed that in-
creasing recipient age (HR, 1.032 per year; 95% CI, 1.002-
1.063; P = 0.034), donor 60 years or older (HR, 3.138;
95%CI, 1.723-5.715;P < 0.001), and inductionwith IL2Mab
(HR, 0.499; 95% CI, 0.268-0.929; P = 0.028 in favor of
rATG) were predictors of overall graft loss. Donor 60 years
or older (HR, 3.135; 95% CI, 1.716-5.729; P < 0.001) and
IL2Mab induction (HR, 0.503; 95% CI, 0.269-0.940;
P = 0.031 in favor of rATG) remained statistically significant
at multivariate analysis (-2ln likelihood: 371.632; model
summary: χ2(3) = 20.200, P < 0.001). Characteristics of re-
cipients experiencing premature graft loss versus patients
with a functioning graft after 5 years of follow-up are detailed
in Table 2.
Secondary Outcomes
One- and 5-year PS for old DCD and young DCD were
80% versus 94% and 66% versus 85%, respectively
(P = 0.014). The PS distributions were significantly different
with log-rank P = 0.014 (Figure 2). Causes of death in old
DCDwere: sepsis (n = 8), sudden cardiac death (n = 3), spon-
taneous rupture of a liver hemangioma (n = 1), and cancer
(n = 1). Causes of death in young DCD were: sepsis (n = 4),
sudden cardiac death (n = 4), stroke (n = 1), and myocardial
TABLE 1.
Baseline characteristics of primary single kidney transplants
from Maastricht category-III DCD donors <60 (young DCD)
and ≥ 60 years (old DCD)
Variables
Young DCD
(n = 72)
Old DCD
(n = 40)
PMedian (IQR) or n (%)
Recipient male sex 43/72 (59.7) 28/40 (70.0) 0.312
Recipient age, y 49.3 (39.6-55.2) 59.4 (55.4-63.9) <0.001
Recipient age ≥ 60 y 7/72 (9.7) 19/40 (47.5) <0.001
White ethnicitya 26/70 (37.1) 16/38 (42.1) 0.681
Afro-Caribbean ethnicitya 21/70 (30.0) 7/38 (18.4) 0.252
Primary kidney disease:
Primary or secondary glomerulonephritis 13/72 (18.1) 8/40 (20.0) 0.805
IgA nephropathy 3/72 (4.2) 4/40 (40.0) 0.246
Diabetic nephropathy 8/72 (11.1) 6/40 (15.0) 0.563
Polycystic kidney disease 12/72 (16.7) 4/40 (10.0) 0.408
Hypertensive nephrosclerosis 10/72 (13.9) 2/40 (5.0) 0.207
Tubulointerstitial disease 10/72 (13.9) 9/40 (22.5) 0.296
Genetic kidney disease 4/72 (5.6) 0/40 (0.0) 0.295
Unknown 13/72 (18.1) 8/40 (20.0) 0.805
Preemptive transplant 1/72 (1.4) 1/40 (2.5) 1.000
Recipient cytomegalovirus IgG positiveb 52/68 (76.5) 29/39 (74.4) 0.818
Recipient body mass index, kg/m2 26.0 (23.6-29.4) 26.3 (24.4-29.4) 0.657
Recipient body mass index ≥30 kg/m2 16/72 (22.2) 8/40 (20.0) 1.000
Pretransplant diabetes mellitus 9/72 (12.5) 10/40 (25.0) 0.116
Pretransplant cardiovascular disease 4/72 (5.6) 6/40 (15.0) 0.163
Thrombophilia 5/72 (6.9) 3/40 (7.5) 1.000
Donor male sex 41/72 (56.9) 21/40 (52.5) 0.695
Donor age, y 42.5 (29.5-51.8) 64.0 (62.0-68.0) <0.001
HLA mismatch (n) 4 (3-4) 4 (3-5) 0.290
cRF (n): 0 (0-0) 0 (0-0) 0.869
0% 57/72 (79.2) 31/40 (77.5) 0.815
1-10% 8/72 (11.1) 5/40 (12.5) 1.000
11-50% 4/72 (5.6) 3/40 (7.5) 0.699
51-80% 2/72 (2.8) 1/40 (2.5) 1.000
> 80% 1/72 (1.4) 0/40 (0.0) 1.000
CIT, h 14.0 (12.0-17.0) 14.0 (12.6-17.5) 0.810
Anastomosis time, min 25.0 (23.0-28.5) 23.5 (21.0-26.8) 0.146
Graft with multiple arteries 17/72 (23.6) 6/40 (15.0) 0.336
Carrel patch sacrifice 8/72 (11.1) 6/40 (15.0) 0.563
rATG induction 58/72 (80.6) 29/40 (72.5) 0.351
Basiliximab induction 5/72 (6.9) 5/40 (12.5) 0.326
Daclizumab induction 9/72 (12.5) 6/40 (15.0) 0.775
Cyclosporine-MMF-steroid maintenance 72/72 (100) 40/40 (100) 1.000
Follow-upc, mo 60.9 (35.4-85.5) 57.5 (16.1-77.9) 0.250
a Four (3.6%) of 112 missing cases.
b Five (4.5%) of 112 missing cases.
c The follow-up was interrupted on December 2017 and/or in case of recipient death.
cRF, calculated reaction frequency; IQR, interquartile range; MMF, mycophenolate mofetil.
FIGURE 2. Actuarial Kaplan-Meier PS (A), overall GS (B), and death-
censored GS (C) curves for primary single kidney transplants from
Maastricht category-III DCD donors <60 years (young DCD, dashed
line) and ≥ 60 years (old DCD, continuous line).
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age (HR, 1.081 per year; 95% CI, 1.033-1.130; P = 0.001),
recipient 60 years or older (HR, 2.805 per year; 95% CI,
1.291-6.092; P = 0.009), and donor 60 years or older (HR,
2.433; 95%CI, 1.178-5.447; P = 0.017) were significant pre-
dictors of death. Only recipient age (HR, 1.081 per year;
95% CI, 1.033-1.130; P = 0.001) remained statistically sig-
nificant at multivariate analysis.
One- and 5-year death-censored GS in old DCD and
young DCD were 77% versus 90% and 63% versus 83%,
TABLE 2.
Characteristics of primary single kidney transplants from
Maastricht category-III DCD donors with premature graft loss
(Graft loss) or 5-year transplant survival (GS)
Variables
GS
(n = 67)
Graft loss
(n = 45)
PMedian (IQR) or n (%)
Recipient male sex 43/67 (64.2) 28/45 (62.2) 0.844
Recipient age, y 52.1 (41.8-58.3) 55.9 (46.2-62.3) 0.070
Recipient age ≥ 60 y 13/67 (19.4) 13/45 (28.9) 0.262
White ethnicitya 26/65 (40.0) 16/43 (37.2) 0.842
Afro-Caribbean ethnicitya 16/65 (24.6) 12/43 (27.9) 0.823
Primary kidney disease:
Primary or secondary glomerulonephritis 12/67 (17.9) 9/45 (20.0) 0.809
IgA nephropathy 4/67 (6.0) 3/45 (6.7) 1.000
Diabetic nephropathy 11/67 (16.4) 3/45 (6.7) 0.154
Polycystic kidney disease 10/67 (14.9) 6/45 (13.3) 1.000
Hypertensive nephrosclerosis 6/67 (9.0) 6/45 (13.3) 0.539
Tubulointerstitial disease 9/67 (13.4) 10/45 (22.2) 0.305
Genetic kidney disease 4/67 (6.0) 0/45 (0.0) 0.147
Unknown 13/67 (19.4) 8/45 (17.8) 1.000
Thrombophilia 7/67 (10.4) 1/45 (2.2) 0.141
Preemptive transplant 1/67 (1.5) 1/45 (2.2) 1.000
HLA mismatch 3 (3-4) 4 (3-5) 0.206
cRF (n): 0 (0-0) 0 (0-4) 0.160
0% 56/67 (83.6) 32/45 (71.1) 0.158
1-10% 5/67 (7.5) 8/45 (17.8) 0.133
11-50% 4/67 (6.0) 3/45 (6.7) 1.000
51-80% 1/67 (1.5) 2/45 (4.4) 0.563
> 80% 1/67 (1.5) 0/45 (0.0) 1.000
Recipient body mass index, kg/m2 26.0 (22.7-29.4) 26.4 (24.8-30.0) 0.222
Pretransplant diabetes mellitus 12/67 (17.9) 7/45 (15.6) 0.803
Pretransplant cardiovascular disease 6/67 (9.0) 4/45 (8.9) 1.000
Donor male sex 35/67 (52.2) 27/45 (60.0) 0.444
Donor age, y 47.0 (29.0-56.0) 61.0 (50.5-68.0) <0.001
Donor age ≥ 60 y 15/67 (22.4) 25/45 (55.6) 0.001
CIT, h 14.0 (12.0-16.0) 15.0 (12.0-19.0) 0.151
CIT > 12 h 42/67 (62.7) 33/45 (73.3) 0.307
Graft with multiple arteries 15/67 (22.4) 8/45 (17.8) 0.638
Carrel patch sacrifice 10/67 (14.9) 4/45 (8.9) 0.397
Anastomosis time, min 25.0 (23.0-27.0) 24.0 (21.0-29.5) 0.793
rATG induction 57/67 (85.1) 30/45 (66.7) 0.036
IL2Mab induction 10/67 (14.9) 15/45 (33.3) 0.035
Cyclosporine-MMF-steroid maintenance 67/67 (100.0) 45/45 (100.0) 1.000
Microthrombosisb 4/45 (8.9) 2/26 (7.7) 1.000
ATNb 31/45 (68.9) 21/26 (80.8) 0.405
GO ≥10%b 11/45 (24.4) 9/26 (34.6) 0.417
a Four (3.6%) of 112 missing cases.
b Forty-one (36.6%)112 missing cases.
TABLE 3.
Characteristics and outcomes of primary single kidney
transplants from Maastricht category-III DCD donors with
PGF (PGF group) or DGF (DGF group)
Variables
PGF (n = 50) DGF (n = 62)
PMedian (IQR) or n (%)
Recipient male sex 31/50 (38.0) 40/62 (64.5) 0.845
Recipient age, y 42.1 (35.8-55.8) 52.7 (48.0-60.9) 0.001
Recipient age ≥ 60 y 6/50 (12.0) 20/62 (32.3) 0.014
White ethnicitya 25/49 (51.0) 17/59 (28.8) 0.029
Afro-Caribbean ethnicitya 12/49 (24.5) 16/59 (27.1) 0.827
Primary kidney disease:
Primary or secondary glomerulonephritis 7/50 (14.0) 14/62 (22.6) 0.331
IgA nephropathy 1/50 (2.0) 6/62 (9.7) 0.128
Diabetic nephropathy 5/50 (10.0) 9/62 (14.5) 0.572
Polycystic kidney disease 7/50 (14.0) 9/62 (14.5) 1.000
Hypertensive nephrosclerosis 7/50 (14.0) 5/62 (8.1) 0.367
Tubulo-interstitial disease 7/50 (14.0) 12/62 (19.4) 0.614
Genetic kidney disease 3/50 (6.0) 1/62 (1.6) 0.323
Unknown 12/50 (24.0) 9/62 (14.5) 0.230
Thrombophilia 5/50 (10.0) 3/62 (4.8) 0.463
Preemptive transplant 2/50 (4.0) 0/62 (0.0) 0.197
Recipient body mass index, kg/m2 26.3 (22.1-29.4) 24.9 (22.1-27.8) 0.306
Pretransplant diabetes mellitus 7/50 (14.0) 12/62 (19.4) 0.614
Pretransplant cardiovascular disease 6/50 (12.0) 4/62 (6.5) 0.337
Donor male sex 22/50 (44.0) 40/62 (64.5) 0.036
Donor age, y 42.0 (25.5-52.0) 49.0 (28.0-64.0) 0.010
Donor age ≥ 60 y 12/50 (24.0) 28/62 (45.2) 0.029
HLA mismatch 3 (2-3) 3 (3-4) 0.233
cRF (n): 0 (0-0) 0 (0-0) 0.622
0% 38/50 (76.0) 50/62 (80.6) 0.645
1-10% 7/50 (14.0) 6/62 (9.7) 0.559
11-50% 4/50 (8.0) 3/62 (4.8) 0.698
51-80% 1/50 (2.0) 2/62 (3.2) 1.000
> 80% 0/50 (0.0) 1/62 (1.6) 1.000
CIT, h 14.0 (11.8-16.0) 14.0 (12.0-17.0) 0.979
CIT > 12 h 30/50 (60.0) 45/62 (72.6) 0.225
Graft with multiple arteries 12/50 (24.0) 11/62 (17.7) 0.484
Carrel patch sacrifice 8/50 (16.0) 6/62 (9.7) 0.393
Anastomosis time (minutes) 25.0 (22.5-30.0) 24.0 (21.0-26.0) 0.333
rATG induction 40/50 (80.0) 47/62 (75.8) 0.653
Basiliximab induction 4/50 (8.0) 6/62 (9.7) 1.000
Daclizumab induction 6/50 (12.0) 9/62 (14.5) 0.785
Cyclosporine-MMF-steroid maintenance 50/50 (100.0) 62/62 (100.0) 1.000
Microthrombosisb 2/28 (7.1) 4/43 (9.3) 1.000
ATNb 23/28 (82.1) 29/43 (67.4) 0.272
GO ≥10%b 7/28 (25.0) 13/43 (30.2) 0.788
1-y eGFR <30 mL/min per 1.73 m2 16/50 (32.0) 28/62 (45.2) 0.177
BPR 12/50 (24.0) 11/62 (17.7) 0.484
1-y eGFR,mL/min per 1.73 m2 49.0 (36.5-62.5) 46.0 (34.0-50.0) 0.010
3-y eGFR, mL/min per 1.73 m2 44.0 (32.0-58.0) 46.0 (34.0-55.0) 0.478
5-y eGFR, mL/min per 1.73 m2 43.0 (30.0-58.5) 41.0 (29.0-48.0) 0.469
Graft thrombosis 1/50 (2.0) 5/62 (8.1) 0.222
NODATc 3/43 (7.0) 7/50 (14.0) 0.331
PVAN 1/50 (2.0) 4/62 (5.4) 0.378
a Four (3.6%) of 112 missing cases.
b Forty-one (36.6%) of 112 missing cases.
c Comprises only patients with no diabetes at baseline (93/112, 83.0%).
© 2018 Wolters Kluwer Favi et al 5respectively (log-rank P = 0.033). Death-censored GS distri-
bution for the 2 arms was significantly different with log-
rank P less than 0.001 (Figure 2). Univariate Cox regression
analyses for death-censored graft loss identified only donor
60 years or older (HR, 2.363; 95% CI, 1.039-5.373;
P = 0.040) as a significant predictor. As a consequence, no
multivariate analysis could be performed.
The proportion of recipients with 1-year eGFR less than
30 mL/min per 1.73 m2 was 23.5% in young DCD and
41.0% in old DCD (P = 0.057). At univariate analysis, increas-
ing donor age (OR, 1.042 per year; 95% CI, 1.010-1.074;
FIGURE 3. Actuarial Kaplan-Meier PS (A), overall GS (B), and death-
censored GS (C) curves for primary single kidney transplants from
Maastricht category-III DCD donors with PGF (dashed line) and
DGF (continuous line).
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P = 0.019) were predictors of poor eGFR. A multivariate logis-
tic regression model was not feasible because histology was
available only for 63.4% patients.
PNF rates were 5.6% in young DCD and 5% in old DCD
(P = 1.000).
We observed 70% DGF in old DCD and 47.2% in young
DCD (P = 0.029). At univariate analysis, recipient 60 years or
older (OR, 3.492; 95% CI, 1.278-9.545; P = 0.015), donor
60 years or older (OR, 2.608; 95% CI, 1.149-5.917;
P = 0.022), and donor sex (OR, 0.432; 95% CI, 0.201-
0.927; P = 0.031 in favor of female donors) were significant
predictors. The subsequent multivariate logistic regression
model (Nagelkerke R2 = 0.234; Hosmer and Lemeshow χ2
test = 10.336; P = 0.242; χ2(3) = 21.485, P < 0.001) showed
that only donor male sex was associated with DGF (adjusted
OR, 0.334; 95%CI, 0.142-0.783;P = 0.012). Characteristics
and outcomes of KTx with primary graft function (PGF) or
DGF are shown in Table 3. Kaplan-Meier survival analysis
of recipients with PGF versus DGF showed similar PS and
GS curves (Figure 3).
As detailed in Table 4, 5-year cumulative incidence of BPR
was 15% in old DCD versus 23.6% in young DCD (log-rank
P = 0.613).
Five-year eGFR for old DCD and young DCD was 34.0
(27.0-42.0) and 45.0 (33.0-58.0) mL/min per 1.73 m2, re-
spectively (P = 0.021).
Graft-related surgical complication rate was 22.5% in old
DCD and 6.9% in youngDCD (P = 0.017). Complications in
young DCD were: lymphoceles (n = 3), ureteral stenosis
(n = 1), and graft thrombosis (n = 1). In old DCD, we re-
corded graft thrombosis (n = 5), lymphoceles (n = 3), and ure-
teral leak (n = 1). The proportion of patients experiencing
graft thrombosis was 12.5% in old DCD versus 1.4% in
young DCD (P = 0.021). As only 6 graft thrombosis were
reported, correspondent inferential statistics was not possi-
ble. Nevertheless, comparison between transplants with or
without graft thrombosis showed statistically significant
differences in donor age (62.5, 53.8-73.5 vs 51.5, 36.8-
62.0 years; P = 0.048), proportion of grafts from donors
≥60 years (5/6, 83.3% vs 35/106, 33%; P = 0.021), and pro-
portion of grafts with GO (4/5, 80% vs 16/66, 24.2%;
P = 0.020).
Overall PVAN, NODAT, and PTLD rates were not signif-
icantly different (Table 4).
Postimplantation Biopsy
A PIB was obtained in 63.9% young DCD and 70% old
DCD (P = 0.5). Prevalence of ATN and microthrombosis in
young DCD and old DCD were, respectively, 75.6% versus
69.2% (P = 0.588) and 11.1% versus 3.8% (P = 0.404). Me-
dian number of obsolete glomeruli was 8.1 (0.0-12.5) in old
DCD versus 0.0 (0.0-6.9) in youngDCD (P = 0.016). GO sig-
nificantly predicted 1-year eGFR <30 mL/min per 1.73 m2 in
univariate logistic regression (P = 0.019).
DBD Control Group
Characteristics of old DCD and old DBD are described in
Table 5. As shown in Figure 4, 5-year PS for oldDCDand old
DBD was 66% versus 67%, respectively (log-rank
P = 0.394). Causes of death in old DBD were: sepsis (n = 8)
and sudden cardiac death (n = 4). Five-year overall and
TABLE 4.
Main results after 5 years of follow-up for primary single
kidney transplants from Maastricht category-III DCD donors
<60 (young DCD) and ≥ 60 years (old DCD)
Variables
Young DCD (n = 72) Old DCD (n = 40)
PMedian (IQR) or n (%)
1-year eGFR <30 mL/min per
1.73 m2
16/68 (23.5)a 16/39 (41.0)b 0.057
PNF 4/72 (5.6) 2/40 (5.0) 1.000
DGF 34/72 (47.2) 28/40 (70.0) 0.029
5-y BPR 17/72 (23.6) 6/40 (15.0) 0.613
5-y BPR (n) 19 6 —
Cell-mediated (n) 11 4 —
Antibody-mediated (n) 4 1 —
Borderline (n) 2 1 —
Steroid-resistant (n) 2 0 —
1-year eGFR, mL/min per 1.73 m2 49.0 (37.0-62.0)c 36.0 (28.5-47.0)d 0.001
3-year eGFR, mL/min per 1.73 m2 49.0 (37.0-58.0)e 34.0 (29.0-48.0)f 0.028
5-year eGFR, mL/min per 1.73 m2 45.0 (33.0-58.0)g 34.0 (27.0-42.0)h 0.021
Graft thrombosis 1/72 (1.4) 5/40 (12.5) 0.021
NODATi 8/63 (12.7) 2/30 (6.7) 0.492
PVAN 3/72 (4.2) 2/40 (5.0) 1.000
PTLD 0/72 (0.0) 1/40 (2.5) 0.357
a Sixty-eight (94.4%) of 72 valid cases.
b Thirty-nine (97.5%) of 40 valid cases.
c Fifty-seven (79.2%) of 72 valid cases.
d Twenty-thee (57.5%) of 40 valid cases.
e Fifty-one (70.8%) of 72 valid cases.
f Eighteen (45.0%) of 40 valid cases.
g Thirty-nine (54.2%) of 72 valid cases.
h Thirteen (32.5%) of 40 valid cases.
i Comprises only patients with no diabetes at baseline (93/112, 83.0%).
TABLE 5.
Baseline characteristics of primary single kidney transplants
from Maastricht category-III DCD (old DCD) and DBD (old
DBD) donors ≥60 years
Variables
Old DBD
(n = 40)
Old DCD
(n = 40)
PMedian (IQR) or n (%)
Recipient male sex 20/40 (50.0) 28/40 (70.0) 0.110
Recipient age, y 56.5 (50.3-65.5) 59.0 (55.0-63.0) 0.534
Recipient age ≥ 60 y 15/40 (37.5) 19/40 (47.5) 0.498
White ethnicitya 12/37 (32.4) 16/38 (42.1) 0.476
Afro-Caribbean ethnicitya 7/37 (18.9) 7/38 (18.4) 1.000
Primary kidney disease:
Primary or secondary glomerulonephritis 5/40 (12.5) 8/40 (20.0) 0.546
IgA nephropathy 2/40 (5.0) 4/40 (10.0) 0.675
Diabetic nephropathy 4/40 (10.0) 6/40 (15.0) 0.737
Polycystic kidney disease 5/40 (12.5) 4/40 (10.0) 1.000
Hypertensive nephrosclerosis 4/40 (10.0) 2/40 (20.0) 0.675
Tubulointerstitial disease 5/40 (12.5) 9/40 (22.5) 0.378
Genetic kidney disease 1/40 (2.5) 0/40 (0.0) 1.000
Unknown 14/40 (35.0) 8/40 (20.0) 0.210
Preemptive transplant 1/40 (2.5) 1/40 (2.5) 1.000
Recipient cytomegalovirus IgG positiveb 31/38 (81.6) 29/39 (74.4) 0.584
Recipient body mass index, kg/m2 25.1 (23.0-27.5) 26.3 (24.4-29.4) 0.119
Pretransplant diabetes mellitus 4/40 (10.0) 10/40 (25.0) 0.139
Pretransplant cardiovascular disease 4/40 (10.0) 6/40 (15.0) 0.737
Donor male sex 21/40 (52.5) 21/40 (52.5) 1.000
Donor age, y 66.0 (62.0-71.0) 64.0 (62.0-68.0) 0.299
© 2018 Wolters Kluwer Favi et al 7death-censored GS for oldDCD and oldDBDwere 39% ver-
sus 48% (log-rank P = 0.138) and 63% versus 69%, respec-
tively (log-rank P = 0.518). Causes of graft loss in old DBD
were: death with function (n = 8), graft thrombosis (n = 2),
IF/TA (n = 2), PNF (n = 1), PVAN (n = 1), recurrent renal dis-
ease (n = 2), antibody-mediated rejection (n = 1), and cancer
(n = 1). PNF and DGF in old DBD and in old DCD were
2.5% versus 5% (P = 1.000) and 37.5% versus 70%, respec-
tively (P = 0.007). Five-year eGFR was 41.0 (40.0-42.0) in
old DBD and 34.0 (27.0-42.0) mL/min per 1.73 m2 in old
DCD (P = 0.029). Five-year BPR and graft-related surgical
complication rates were similar (P = 1.000). Outcomes of
old DCD and old DBD are summarized in Table 6.HLA mismatch 3.0 (3.0-4.0) 4.0 (3.0-5.0) 0.179
CIT, h 15.0 (13.0-20.8) 14.0 (12.6-17.5) 0.070
CIT > 12 h 34/40 (85.0) 31/40 (77.5) 0.568
Anastomosis time, min 26.5 (22.3-30.8) 23.5 (21.0-26.8) 0.085
Graft with multiple arteries 8/40 (20.0) 6/40 (15.0) 0.770
Carrel patch sacrifice 9/40 (22.5) 6/40 (15.0) 0.568
rATG induction 9/40 (22.5) 29/40 (72.5) <0.001
Basiliximab induction 14/40 (35.0) 5/40 (12.5) 0.034
Daclizumab induction 17/40 (42.5) 6/40 (15.0) 0.013
Cyclosporine-MMF-steroid maintenance 40/40 (100) 40/40 (100) 1.000
Follow-upc, mo 60.0 (18.4-92.6) 57.5 (16.1-77.9) 0.194
a Five (6.3%) of 112 missing cases.
b Three (3.8%) of 112 missing cases.
c The follow-up was interrupted on December 2017 and/or in case of patient loss.DISCUSSION
In the United Kingdom, the immense efforts produced by
the Organ Donation and Transplantation services have led
to a remarkable increase of organs donated and transplanted.
In 2016 to 2017, we achieved the highest number of trans-
plants performed in the Country: 3710 from 1413 deceased
donors. This impressive result would not have been possible
without DCD as they actually represented 41% of all de-
ceased donors.19 The National Kidney Transplant Waiting
List has been also evolving. More than 20% of all KTx can-
didates are now older than 60 years.20 In these patients, the
window of opportunity for transplantation is rather narrowbecause comorbidities may reduce the chances of receiving
a kidney or jeopardize posttransplant outcomes.21 The avail-
ability of large numbers of organs from elderly DCD (42%of
all DCD donors recorded in 2016-2017) deserves some spe-
cial considerations on how to guarantee the best utilization.13
Age discrepancy between donor and recipient is a limiting
factor for using kidneys from elderly donors. However, the
development of old-for-old allocation strategies along with
a wise use of preimplantation histology have allowed optimi-
zation of EC-DBD kidneys.22-25 Initial experience with DCD
showed poor GSwith high rates of PNF and DGF.3-5 Further
studies in following years demonstrated encouraging im-
provements but general concern regarding the use of
EC-DCD has not faded.26,27 The definition of EC-DCD kid-
neys comes from the one applied to DBD and does not take
into account Maastricht categories, warm ischemia time
(WIT), organ preservation modality, or age-dependant
FIGURE 4. Actuarial Kaplan-Meier PS (A), overall GS (B), and death-
censored GS (C) curves for primary single kidney transplants from
Maastricht category-III DCD (old DCD, continuous line) and DBD
(old DBD, dashed line) donor ≥60 years.
8 Transplantation DIRECT ■ 2018 www.transplantationdirect.comsusceptibility to ischemia-reperfusion injury. With such limi-
tations, it is difficult to provide adequate informed consent
to our patients, as the impact of several variables remains un-
clear. We focused on category-III DCD and investigated the
relationship between donor age and transplant outcomes in
the setting of an old for-old allocation policy. To reduce bias,
only organs preserved on SCS and transplanted in de novo
recipients on the same immunosuppressive scheme were con-
sidered.We chose 60 years as a cut-off to discriminate between
younger and older donors because such a parameter is widely
accepted per se to define both EC-DBD and EC-DCDkidneys.
In line with another UK study and with more recent data
from the Eurotransplant Senior Program, our experience
shows that KTx from DCD 60 years or older have inferior
PS, GS, and function than DCD younger than 60 years.7,28
As described in old for-old DBD KTx, we found that the risk
of graft loss is highest during the first year with death repre-
senting the leading cause of failure.13,29 Nevertheless, 5-year
death-censored GS of the present series is reasonable enough
to promote KTx from elderly DCD in age-matched recipi-
ents. Comparison between DCD and DBD ≥ 60 years sup-
ports this point of view as it demonstrated similar PS and
GS.6,28 How the difference in eGFR observed between KTx
from elderly DCD and DBD may affect long-term outcomes
remains unclear. Theoretically, the inferior life expectancy
of elderly recipients should overcome the risk of premature
transplant loss due to chronic deterioration of function but
longer follow-up is needed to confirm this hypothesis.30 Data
on elderly patients receiving EC-DBD have shown a survival
advantage over dialysis but there are no data demonstrating
a survival benefit for primary EC-DCD KTx recipients over
patients remaining on dialysis or waiting for a SC-DCD, a
SC-DBD or an EC-DBD.13,28 As long as PS and GS remain
similar for KTx from elderly DCD and DBD donors, we
can assume that a comparable survival benefit may be ex-
pected. However, this may not be enough to reassure theTABLE 6.
Main results after 5 years of follow-up for primary single
kidney transplants from Maastricht category-III DCD (old
DCD) and DBD (old DBD) donors ≥60 years
Variables
Old DBD (n = 40) Old DCD (n = 40)
PMedian (IQR) or n (%)
1-y eGFR <30 mL/min per 1.73 m2 8/39 (20.5)a 16/39 (41.0)b 0.049
PNF 1/40 (2.5) 2/40 (5.0) 1.000
DGF 15/40 (37.5) 28/40 (70.0) 0.007
5-y BPR 7/40 (17.5) 6/40 (15.0) 1.000
1-y eGFR, mL/min per 1.73 m2 41.0 (38.3-45.8)c 35.0 (28.0-46.0)d 0.023
5-year eGFR, mL/min per 1.73 m2 41.0 (40.0-42.0)e 34.0 (27.0-42.0)f 0.029
Graft thrombosis 2/40 (5.0) 5/40 (12.5) 0.432
NODATg 2/40 (5.6) 2/40 (6.7) 1.000
Polyomavirus-associated nephropathy 4/40 (10.0) 2/40 (5.0) 0.675
PTLD 0/40 (0.0) 1/40 (2.5) 1.000
a Thirty-nine (97.5%) of 40 valid cases.
b Thirty-nine (97.5%) of 40 valid cases.
c Twenty-eight (70.0%) of 40 valid cases.
d Twenty-three (57.5%) of 40 valid cases.
e Fifteen (37.5%) of 40 valid cases.
f Thirteen (32.5%)of 40 valid cases.
g Comprises only patients with no diabetes at baseline (66/80, 82.5%).
© 2018 Wolters Kluwer Favi et al 9public on the beneficial use of such organs often addressed as
“marginal.”To support those transplant centers that are will-
ing to consider a full utilization of the DCD donor pool cur-
rently available, regulatory bodies might consider extracting
data of EC-DCDKTx and comparing outcomes, with specific
reference to survival benefit versus other renal replacement
therapies.
Delayed graft function inKTx from elderlyDCDwas signif-
icantly higher than younger DCD and age-matched DBD.3-5
We could not demonstrate any direct effects of DGF on GS
or function but impact of DGF onDCDKTx remains contro-
versial.12,31 Especially for elderly patients, DGFmay represent
a severe complication because it is often associated with pro-
longed dialysis, drug-related side effects, rejection, and car-
diovascular events.32 Detrimental effects of CIT on DGF
can be substantially mitigated having local and national pol-
icies restricting EC-DCD KTx only when a CIT less than
12 hours may be expected. Routine use of HMP for DCD
kidneys is still debated but it may help assess organ viability
and reduce DGF.33 Organ procurement using normothermic
perfusion has shown promising results but ethical issues, lo-
gistical difficulties, and high costs restrict application of the
technique to highly specialized centers.34 WIT is another risk
factor for DGF.35 Optimal donor management and sound
surgical technique during organ procurement and transplant
are key factors for reducing total WIT.36
With such a combination of poor quality organs, DGF, re-
jection, and frail recipients, careful selection of immunosup-
pression is mandatory. Our multivariate regression model
showed that rATG induction was associated with better GS
than anti–IL2-Mab. Albeit the study was not designed to
compare induction treatments, such a result deserves further
investigation. To the best of our knowledge, this is the first re-
port on a beneficial effect of rATG inDCD transplants receiv-
ing a cyclosporine-based maintenance. The fact that most
European centers use tacrolimus rather than cyclosporine
may limit the value of this finding. However, there are still
thousands of transplant patients around the world receiving
cyclosporine as chronic immunosuppression (ie, atypical
hemolytic uremic syndrome, tacrolimus-related side effects,
diabetes, financial constrains). This subgroup of recipients
might actually benefit from an ATG-based induction scheme.
rATG induction in DCD KTx offers several advantages as it
allows to reduce the risk of rejection, the need for early biopsy,
and the exposure to calcineurin inhibitors.37 Indeed, we ob-
served low rejection rates in both the DCD groups. More-
over, rejection rate in elderly DCD was similar to DBD.
These results are encouraging as elderly recipients of elderly
DCD are at increased risk of rejection than elderly recipients
of youngDCD orDBD.28,38 At the same time, we realize that
sepsis was an important cause of death among our patients.
Elderly recipients are more prone to infections.39 Moreover,
higher infection rates have been recently reported in DCD
KTx.40 Our experience supports these findings and suggest
to further reduce the net state of immunosuppression.
Lower-dose rATG in associationwith basiliximabmay repre-
sent a valid alternative to standard-dose rATG.41 Calcineurin
inhibitor minimization protocols should be also favored as
they may damper infection, diabetes, cancer, and IF/TA.42
It is well known that elderly patients are more likely to ex-
perience complications after major surgical procedures.43
Our results are in linewith other studies and show that elderlyrecipients receiving an elderly DCD kidney have more com-
plications than their younger counterpart.39 Overall postop-
erative surgical complication rates in elderly DCD and DBD
recipients were not significantly different. However, we ob-
served a very high incidence of graft thrombosis in transplants
from elderly DCD. This finding is difficult to explain. We
check the quality of kidney perfusion as soon as the organ
arrives at the hospital. Recipients are assessed by Doppler-
ultrasound before leaving the theater, every day as long as
DGF is suspected, and any times there is a decrease in urinary
output.44 All patients also receive tailored DVT prophylaxis
for 2 to 4 weeks after the operation. Higher rate of graft
thrombosis has been reported in DCD pancreas transplants
but there are no data suggesting that DCD KTx may have
an increased risk of thrombosis nor studies addressing this
specific issue in KTx from elderly donors.45 We could not
find any associations between graft thrombosis and DCD
transplant characteristics other than donor age and GO. A
possible explanation is that the increased incidence of throm-
bosis could have been related to DGF, which was also more
frequently observed in elderly DCD transplants. Perfusion
impairment has been demonstrated in grafts with DGF.46
High vascular resistances in the capillary bed and parenchy-
mal edema can generate high intraparenchymal pressures
eventually leading to engorgement and thrombosis. In-
creased susceptibility to ischemia-reperfusion injurymay also
play a role.
Finally, our analysis of PIB did not reveal any associations
between ATN and DCD KTx survival. This finding is inter-
esting because, compared with preimplantation histology,18
PIB can assess both the components of ischemia-reperfusion
injury and better evaluate the spectrum of ATN. As previ-
ously reported, whether severe ATNmay be associated to in-
ferior outcomes after DCD KTx remains unclear.18 Larger
populations are needed to address this issue in transplants
with such a high prevalence of ATN. Nonetheless, our data
show that GO may predict loss of function within the first
posttransplant year. As GO is strictly related to renal senes-
cence, this finding confirms that age is an important and inde-
pendent risk factor for poor transplant outcomes and should
foster constant biopsy sampling of EC-DCD kidneys in fu-
ture trials.
Main limitations of the present study are the relatively small
sample size and the arbitrary allocation of kidneys from el-
derly donors to age-matched recipients. In particular, the
lack of donor randomization did not allow to fully rule out
the relative impact of recipient age on transplant outcomes.
We believe that old for-old transplantation is the best option
for optimizing results of EC kidneys and when planning the
study we considered nonethical to propose elderly donors
to young recipients. Furthermore, regression analysis demon-
strated the independent effect of donor age on PS and GS and
confirmed that donor age 60 years or older can be a valuable
parameter to identify high-risk category-III DCD donors.
Our unit, similarly to other centers in the United Kingdom,
has used DCD kidneys without changing any aspects of the
service to adapt to the challenges posed by these organs. In
this series, we did not use preimplantation histology, we ex-
cluded dual KTx and all kidneys that have benefitted from
reconditioning. The main purpose was offering a honest and
consistent representation of a clinical practice that is currently
under evaluation in many transplant programs worldwide.
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